Somatic Cancer

Seraseq® HRD gDNA Low-Positive Mix

0710-2880.jpg
Material Number 0710-2880
Size 2 x 20 uL
Price Please sign in to view pricing.
Inventory Status In Stock
Unit EA

Genomic instability resulting from homologous recombination DNA repair deficiency (HRD) is a response biomarker to assess ovarian and breast cancer patient eligibility for PARP inhibitor and platinum-based therapies. HRD measurements have the potential to improve cancer therapy, however standardizing and democratizing HRD measurements remains challenging due to their inherent complexity. This cell line-derived HRD reference material can support the development, validation, and routine use of assays determining HRD status in cancer patients.

FEATURES

  • Derived from tumor and matched-normal human cell lines
  • Allows blending to desired % tumor content with included SNP-matched normal cell line gDNA
    • 20 µL of both tumor and matched normal gDNA at 25 ng/µL
  • HRD status validated by targeted Next Generation Sequencing (NGS)
  • Manufactured in GMP-compliant, ISO 13485-certified facilities